TrioxBio
Nitric Oxide Synthase Inhibitors
Company Overview
Snapshot
Founded in July 2015 by Shlomo Sadoun and Roy Farfara, TrioxBio operates with 1–10 employees. The company received Fast Track Designation from the U.S. FDA in May 2018 for Raviten® for the treatment of intradialytic hypotension.
Business overview
TrioxBio specializes in the development and commercialization of proprietary synthetic small molecules designed to treat pathological conditions stemming from the overproduction of nitric oxide. The company's core technology involves nitric oxide synthase (NOS) inhibitors, such as its API, S-ethylisothiouronium diethylphosphate (MTR-104), which blocks nitric oxide production to prevent detrimental effects like blood vessel dilation caused by excessive NOS activity. TrioxBio's leading candidate, MTR-107, is indicated for the prevention of recurrent intradialytic hypotension and has received orphan drug designation from the FDA. Operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, the company focuses on drug discovery and delivery, with R&D efforts extending to oncology, antiviral diseases, and new drug-delivery systems as part of SK Pharma Group.
Strategic signal
In May 2018, TrioxBio's drug candidate, Raviten®, received Fast Track Designation from the U.S. FDA for the treatment of intradialytic hypotension. This designation signals regulatory validation and potential for expedited review, indicating a significant step forward in the development and potential market entry of their therapeutic solution for a critical medical need.
Log in to access full profile ›Company Intelligence Q&A
- What is TrioxBio's primary focus?
- TrioxBio develops and commercializes proprietary synthetic small molecules, specifically nitric oxide synthase (NOS) inhibitors, to treat pathologic states caused by the overproduction of nitric oxide.
- Which of TrioxBio's drug candidates received Orphan Drug Designation?
- TrioxBio's leading candidate, MTR-107, indicated for the prevention of recurrent intradialytic hypotension, received orphan drug designation from the FDA in August 2016.
- What significant regulatory milestone did TrioxBio achieve in May 2018?
- In May 2018, TrioxBio announced that its drug Raviten® received Fast Track Designation from the U.S. FDA for the treatment of intradialytic hypotension.
- Who are the founders of TrioxBio?
- TrioxBio was co-founded by Shlomo Sadoun and Roy Farfara.
- What is the current status of TrioxBio?
- TrioxBio is currently Non Active, having ceased to operate in January 2022.